Jun 15, 2022 / 10:20PM GMT
Unidentified Analyst -
Okay. Ladies and gentlemen, welcome to our next session where I'm very pleased to be joined by the team from argenx. I'm [Nick Hallett], I work in the European biopharma team in London. I'm joined today by Keith Woods, Chief Operating Officer; and Beth DelGiacco, the VP of IR. So first of all, welcome to both. It's great to have you here.
R. Keith Woods - argenx SE - COO
Thank you for having us. Pleasure to be here.
Questions and Answers:
Unidentified Analyst -Perhaps, Keith, if we could start, if you could just sort of give a high-level overview of where argenx stands today, where your therapeutic area of focus is?
R. Keith Woods - argenx SE - COO
Sure. So as you know, at argenx, we were born out of engineering antibodies for other companies. Our ambition has expanded into clinical development, and we've kept some of those discoveries in-house first and foremost, is efgartigimod, VYVGART. We now have commercially launched VYVGART in the U.S. and Japan. So we
Trustpilot
